I'll be speaking in a webinar about ROS1+ lung cancer on November 17. Registration is FREE and available here: floridasocietyofclinicaloncologyjune152017.growthzoneapp.com/ap/Events/Re...
Hope you can join us!
Hope you can join us!
November 11, 2025 at 7:47 PM
I'll be speaking in a webinar about ROS1+ lung cancer on November 17. Registration is FREE and available here: floridasocietyofclinicaloncologyjune152017.growthzoneapp.com/ap/Events/Re...
Hope you can join us!
Hope you can join us!
Julia has been living with stage 4 ROS1+ #lungcancer for almost 10 yrs.
It started with what she thought was a chest infection, then pneumonia put her in ICU for 8 days. She’d also had shoulder pain for months, which she put down to sleeping awkwardly. She didn’t know it could be a symptom. #LCSM
It started with what she thought was a chest infection, then pneumonia put her in ICU for 8 days. She’d also had shoulder pain for months, which she put down to sleeping awkwardly. She didn’t know it could be a symptom. #LCSM
November 5, 2025 at 7:04 AM
Julia has been living with stage 4 ROS1+ #lungcancer for almost 10 yrs.
It started with what she thought was a chest infection, then pneumonia put her in ICU for 8 days. She’d also had shoulder pain for months, which she put down to sleeping awkwardly. She didn’t know it could be a symptom. #LCSM
It started with what she thought was a chest infection, then pneumonia put her in ICU for 8 days. She’d also had shoulder pain for months, which she put down to sleeping awkwardly. She didn’t know it could be a symptom. #LCSM
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
https://www.newsbeep.com/il/111831/
Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid tumors in a…
https://www.newsbeep.com/il/111831/
Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid tumors in a…
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors - Israel News Beep
Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid
www.newsbeep.com
November 2, 2025 at 7:45 PM
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
https://www.newsbeep.com/il/111831/
Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid tumors in a…
https://www.newsbeep.com/il/111831/
Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid tumors in a…
The takeaways from the paper are that liver metastases more than brain metastases are predictors of worse outcome in ALK and ros1. But there are other messages
November 1, 2025 at 11:48 PM
The takeaways from the paper are that liver metastases more than brain metastases are predictors of worse outcome in ALK and ros1. But there are other messages
ROS1融合遺伝子陽性NSCLCに新規TKI、耐性変異や脳転移にも有効性期待 - 日経メディカル
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
November 1, 2025 at 10:09 PM
ROS1融合遺伝子陽性NSCLCに新規TKI、耐性変異や脳転移にも有効性期待 - 日経メディカル
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
November 1, 2025 at 9:09 PM
ROS1融合遺伝子陽性NSCLCに新規TKI、耐性変異や脳転移にも有効性期待 - 日経メディカル
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
November 1, 2025 at 8:09 PM
ROS1融合遺伝子陽性NSCLCに新規TKI、耐性変異や脳転移にも有効性期待 - 日経メディカル
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
news.google.com/rss/articles/CBMigwFBVV95cUxPcjZUSi1LWHVVcTFoWmFnVXM5clFvYWVJZEN1eUt3U0ZzQmpuZUdCeFBVR3VPLWpXZkFIUFBXbGN3dTVJM0dvNEREbm53UlJPNG9QcG1CbHQ0ODFjMm93aDBwT2hjVW5Ga3hmQ2FzSS1TbVU4NHROVlBvajBKNmxua2ppQQ?oc=5
November 1, 2025 at 7:09 PM
A meta-analysis of 86 studies on immunotherapy in NSCLC reveals: KRAS G12C & MET amplification show strong responses; EGFR, ALK, HER2, RET, ROS1 exhibit limited benefit from monotherapy; combination therapies significantly improve outcomes. Read more: buff.ly/oH9GKGz #Cancer #NSCLC #Immunotherapy
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis - Jiayan Chen, Wanjun Lu, Mo Chen, Zijing Cai, Ping Zhan, Xin Liu, Suhua Zhu, Mingxiang Ye, Tangfeng Lv, Jiawen Lv, Yong Song, Dong Wang, 2024
Background: Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, ...
buff.ly
October 27, 2025 at 8:15 AM
A meta-analysis of 86 studies on immunotherapy in NSCLC reveals: KRAS G12C & MET amplification show strong responses; EGFR, ALK, HER2, RET, ROS1 exhibit limited benefit from monotherapy; combination therapies significantly improve outcomes. Read more: buff.ly/oH9GKGz #Cancer #NSCLC #Immunotherapy
CYP3A4-Mediated In Vitro and In Vivo Disposition of Lorlatinib
https://www.newsbeep.com/il/97209/
Introduction Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor…
https://www.newsbeep.com/il/97209/
Introduction Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor…
CYP3A4-Mediated In Vitro and In Vivo Disposition of Lorlatinib - Israel News Beep
Introduction
www.newsbeep.com
October 25, 2025 at 11:30 AM
CYP3A4-Mediated In Vitro and In Vivo Disposition of Lorlatinib
https://www.newsbeep.com/il/97209/
Introduction Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor…
https://www.newsbeep.com/il/97209/
Introduction Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor…
This case study describes the successful treatment of a conjunctival inflammatory myofibroblastic tumor with a TFG::ROS1 fusion in a 33-year-old woman. Diagnosis was confirmed through biopsy and RNA sequencing.
October 17, 2025 at 11:14 AM
This case study describes the successful treatment of a conjunctival inflammatory myofibroblastic tumor with a TFG::ROS1 fusion in a 33-year-old woman. Diagnosis was confirmed through biopsy and RNA sequencing.
genomebiology.biomedcentral.com/articles/10....
From the Gehring Lab.
Ros1 prevents paternal hypermethylation of the endosperm genome.
From the Gehring Lab.
Ros1 prevents paternal hypermethylation of the endosperm genome.
Client Challenge
genomebiology.biomedcentral.com
October 13, 2025 at 3:12 PM
genomebiology.biomedcentral.com/articles/10....
From the Gehring Lab.
Ros1 prevents paternal hypermethylation of the endosperm genome.
From the Gehring Lab.
Ros1 prevents paternal hypermethylation of the endosperm genome.
That is truly amazing! Conda-forge rocks! I moved many of our internal projects to conda forge. The catalyst was ROS1 availability via robostack when Ubuntu 20 was EOLd. I am using a tool called #pixi, which I recommend to everyone.
October 9, 2025 at 6:34 PM
That is truly amazing! Conda-forge rocks! I moved many of our internal projects to conda forge. The catalyst was ROS1 availability via robostack when Ubuntu 20 was EOLd. I am using a tool called #pixi, which I recommend to everyone.
However, it had limited sensitivity for detecting gene rearrangements like ALK, ROS1, RET, and NTRK. Liquid biopsy also had a significantly shorter turnaround time compared to standard tests.
October 5, 2025 at 6:18 AM
However, it had limited sensitivity for detecting gene rearrangements like ALK, ROS1, RET, and NTRK. Liquid biopsy also had a significantly shorter turnaround time compared to standard tests.
Product Description
Lorlatinib (PF-06463922) is a third-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase (ALK) and ROS1 fusions, two oncogenic drivers found in a subset of non-small cell lung cancer (NSCLC)
arizona-mall.com/product/lorl...
Lorlatinib (PF-06463922) is a third-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase (ALK) and ROS1 fusions, two oncogenic drivers found in a subset of non-small cell lung cancer (NSCLC)
arizona-mall.com/product/lorl...
Lorlatinib | CAS No. 1454846-35-5
Lorlatinib is a selective, orally active, ATP-competitive inhibitor of ALK and ROS1 kinases. With brain penetration and activity against multiple resistant ALK mutations, it is an essential tool for oncology and targeted therapy research.
arizona-mall.com
October 1, 2025 at 10:26 AM
Product Description
Lorlatinib (PF-06463922) is a third-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase (ALK) and ROS1 fusions, two oncogenic drivers found in a subset of non-small cell lung cancer (NSCLC)
arizona-mall.com/product/lorl...
Lorlatinib (PF-06463922) is a third-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase (ALK) and ROS1 fusions, two oncogenic drivers found in a subset of non-small cell lung cancer (NSCLC)
arizona-mall.com/product/lorl...
This coming week I get to walk among my peer group again for the first time since coming out of the cancer closet. Thursday and Friday in Ottawa (just finished my talk on ROS1 lung cancer). Friday (commute south) and Saturday in DC for a panel on ALK lung cancer.
September 28, 2025 at 9:32 PM
This coming week I get to walk among my peer group again for the first time since coming out of the cancer closet. Thursday and Friday in Ottawa (just finished my talk on ROS1 lung cancer). Friday (commute south) and Saturday in DC for a panel on ALK lung cancer.
DCLung25: Comprehensive Lung Cancer Updates for EGFR, ALK, and ROS1 - Stephen Liu
@stephenvliu.bsky.social
oncodaily.com/voices/377814
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DCLung25 #LungCancer
@stephenvliu.bsky.social
oncodaily.com/voices/377814
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DCLung25 #LungCancer
Stephen Liu: DCLung25 - Comprehensive Lung Cancer Updates for EGFR, ALK, and ROS1 - OncoDaily
Stephen Liu: DCLung25 - Comprehensive Lung Cancer Updates for EGFR, ALK, and ROS1 / cancer, OncoDaily, Oncology, Stephen Liu
oncodaily.com
September 25, 2025 at 3:13 PM
DCLung25: Comprehensive Lung Cancer Updates for EGFR, ALK, and ROS1 - Stephen Liu
@stephenvliu.bsky.social
oncodaily.com/voices/377814
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DCLung25 #LungCancer
@stephenvliu.bsky.social
oncodaily.com/voices/377814
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DCLung25 #LungCancer
🚨Japan Regulatory Update!
✅ Nuvation Bio’s IBTROZITM (taletrectinib) approved by Japan’s Ministry of Health, Labour and Welfare for advanced ROS1-positive NSCLC
➡️ Based on pivotal Phase 2 TRUST studies showing high, durable response rates
🔗 Read more: bit.ly/ONCOnews22S-3
✅ Nuvation Bio’s IBTROZITM (taletrectinib) approved by Japan’s Ministry of Health, Labour and Welfare for advanced ROS1-positive NSCLC
➡️ Based on pivotal Phase 2 TRUST studies showing high, durable response rates
🔗 Read more: bit.ly/ONCOnews22S-3
September 22, 2025 at 2:30 PM
🚨Japan Regulatory Update!
✅ Nuvation Bio’s IBTROZITM (taletrectinib) approved by Japan’s Ministry of Health, Labour and Welfare for advanced ROS1-positive NSCLC
➡️ Based on pivotal Phase 2 TRUST studies showing high, durable response rates
🔗 Read more: bit.ly/ONCOnews22S-3
✅ Nuvation Bio’s IBTROZITM (taletrectinib) approved by Japan’s Ministry of Health, Labour and Welfare for advanced ROS1-positive NSCLC
➡️ Based on pivotal Phase 2 TRUST studies showing high, durable response rates
🔗 Read more: bit.ly/ONCOnews22S-3
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology
www.onclive.com/view/repotre...
www.onclive.com/view/repotre...
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC
Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.
www.onclive.com
September 10, 2025 at 3:42 PM
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology
www.onclive.com/view/repotre...
www.onclive.com/view/repotre...
Grosso modo, un 40-50% di questi pazienti ha un tumore con un’alterazione gene¬tica che si può definire «azionabile» farmacologicamente. Que¬sti geni possono essere Egfr, Ros1, Alk, Ret, Met, Her2, la mutazione specifica G12C di Kras e altri. Cosa significa?
September 9, 2025 at 10:40 AM
Grosso modo, un 40-50% di questi pazienti ha un tumore con un’alterazione gene¬tica che si può definire «azionabile» farmacologicamente. Que¬sti geni possono essere Egfr, Ros1, Alk, Ret, Met, Her2, la mutazione specifica G12C di Kras e altri. Cosa significa?
The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients
👉 buff.ly/X1aoIai
#ROS1 #NSCLC #Oncofusions
👉 buff.ly/X1aoIai
#ROS1 #NSCLC #Oncofusions
September 8, 2025 at 9:45 AM
The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients
👉 buff.ly/X1aoIai
#ROS1 #NSCLC #Oncofusions
👉 buff.ly/X1aoIai
#ROS1 #NSCLC #Oncofusions
Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC @iaslc.bsky.social @mskcancercenter.bsky.social #WCLC25 #lcsm #oncology www.onclive.com/view/zidesam...
Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC
The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.
www.onclive.com
September 7, 2025 at 7:54 PM
Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC @iaslc.bsky.social @mskcancercenter.bsky.social #WCLC25 #lcsm #oncology www.onclive.com/view/zidesam...
Just In: ( NYSE: #NUVB ) Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI(TM) (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
September 7, 2025 at 11:01 AM
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has…
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has…
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has demonstrated remarkable efficacy and durability, particularly in patients who have already undergone prior tyrosine kinase inhibitor (TKI) therapies. Presented at the prestigious International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), these findings herald a new frontier of hope for a patient population with limited therapeutic options.
scienmag.com
September 7, 2025 at 9:38 AM
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has…
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has…